Buerger's disease manifesting nodular erythema with livedo reticularis

ArticleINTERNAL MEDICINE. 46(21):1815-1819(2007)journal articl

Fabrication of ZnSnP(2) thin films by phosphidation

ZnSnP(2) is a promising candidate as a solar absorbing material consisting of earth-abundant and low-toxic elements. In this study, the phosphidation method, where co-sputtered Zn–Sn thin films react with phosphorus gas, was adopted for fabricating ZnSnP(2) thin films. To establish the conditions for producing ZnSnP(2) thin films, we investigated the influence of phosphidation temperature on the product phases, and interpreted the experimental results using chemical potential diagrams of the Zn–Sn–P system. ZnSnP(2) thin films with a single phase were obtained by phosphidation at 500 °C under a phosphorus vapor pressure of 10[−2] atm. However, formation of ZnSnP(2)protrusions was observed on the surface of the thin films. Based on the experimental results and the chemical potential diagrams, it is indicated that un-reacted liquid Sn particles reacted with Zn and phosphorus gas to form ZnSnP(2) protrusions in a manner similar to the vapor-Liquid-Solid growth mode

Suppression of structural imperfection in strained Si by utilizing SiGe bulk substrate

科研費報告書収録論文(課題番号:14102020/研究代表者:中嶋一雄/SiGe基板単結晶の低欠陥化と歪みを制御した機能性ヘテロ構造の創製

Development of the NASA/Baylor VAD

A cooperative effort between the NASA/Johnson Space Center (JSC) and the Baylor College of Medicine (BCM) has been underway since 1988 to develop a long-term implantable Ventricular Assist Device (VAD). The VAD is intended to boost the cardiac output of patients with deteriorated cardiac function. For many of these patients, the best alternative is heart transplantation. Heart transplantation is a complex and expensive procedure and usually requires a long waiting period for a donor heart. The condition of the patient often deteriorates during this waiting period which complicates the pre and post-operative care. Because of these factors, the need for a long-term implantable VAD for use as a bridge-to-transplant device or as a permanent assist device has become the focus of much research. The need for a VAD has been estimated at 50,000 to 60,000 patients per year in the United States alone. A device which satisfies all the system performance and reliability requirements has yet to be achieved. However, the development of the NASA/Baylor VAD has progressed to a state in which commercial viability can being to be considered. The device is small, simple, efficient and reliable which meets all requirements for a totally implantable VAD